Prophylactic effect of brinzolamide–brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections
Tóm tắt
To evaluate the effect of topical prophylaxis with brinzolamide–brimonidine fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF). This prospective comparative study included 56 eyes of 47 patients treated with intravitreal injections of anti-VEGF, and they were randomly divided into two groups. In control group (25 eyes), no prophylactic medication was used, whereas in case group (31 eyes) one drop of a fixed combination of brinzolamide–brimonidine was instilled two hours before the injection. IOP was measured before the injection and at 1 min, 10 min and 30 min post-injection in all eyes. The mean IOP before injection at 1 min, 10 min and 30 min post-injection was 16,6 ± 2,8 mmHg, 53,4 ± 12 mmHg, 26,4 ± 5,5 mmHg and 17,9 ± 4 mmHg, respectively, in control group and 15,1 ± 3,4 mmHg, 42,6 ± 8,4 mmHg, 21,4 ± 5,5 mmHg and 12,4 ± 3,5 mmHg, respectively, in case group. At 1 min, 10 min and 30 min post-injection, the mean IOP was significantly lower in case group compared with control group (p < 0,001, p = 0,0014 and p < 0,0001, respectively), but no difference at the pre-injection IOP between the two groups was found (p = 0,09). The prophylactic administration of one drop of brinzolamide–brimonidine fixed combination significantly reduces the IOP spikes during the first 30 min after the intravitreal anti-VEGF injection.
Tài liệu tham khảo
Bandello F, De Benedetto U, Knutsson KA et al (2011) Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol 5:1303–1308
Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431
Arias L, Planas N, Prades S et al (2008) Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 92:1035–1039
Costa RA, Jorge R, Calucci D et al (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149
Bakri SJ, Pulido JS, McCannel CA et al (2009) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 23:181–185
Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444
Murray CD, Wood D, Allgar V et al (2014) Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye (Lond) 28:1218–1222
Hoguet A, Chen PP, Junk AK et al (2019) The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of ophthalmology. Ophthalmology 126:611–622
Bressler SB, Almukhtar T, Bhorade A et al (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589–597
Eadie BD, Etminan M, Carleton BC et al (2017) Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol 135:363–368
Skalicky SE, Ho I, Agar A et al (2012) Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging 43:328–334
Bracha P, Moore NA, Ciulla TA et al (2018) The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol 63:281–295
El Chehab H, Le Corre A, Giraud JM et al (2012) Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections. J Fr Ophtalmol 35:614–621
Felfeli T, Hostovsky A, Trussart R et al (2019) Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial. Br J Ophthalmol 103:1388–1394
Katayama BY, Bonini-Filho MA, Messias AM et al (2014) Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial. J Glaucoma 23:461–463
Theoulakis PE, Lepidas J, Petropoulos IK et al (2010) Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd 227:280–284
Aung T, Laganovska G, Hernandez Paredes TJ et al (2014) Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology 121:2348–2355
Sharma S, Trikha S, Perera SA et al (2015) Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol 9:2201–2207
Hollands H, Wong J, Bruen R et al (2007) Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 42:807–811
Kim JE, Mantravadi AV, Hur EY et al (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146:930–934
Mojica G, Hariprasad SM, Jager RD et al (2008) Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol 92:584
Shoeibi N, Ghosi Z, Jafari H et al (2021) Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections. Int Ophthalmol 41:1081–1090
Frenkel MP, Haji SA, Frenkel RE (2010) Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 128:1523–1527
Carnota-Mendez P, Mendez-Vazquez C, Otero-Villar J et al (2014) Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Eur J Ophthalmol 24:771–777
Cvetkovic RS, Perry CM (2003) Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 20:919–947
Adkins JC, Balfour JA (1998) Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 12:225–241
Han JA, Frishman WH, Wu Sun S et al (2008) Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev 16:95–108
Kaiserman I, Fendyur A, Vinker S (2009) Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res 34:517–522
van der Valk R, Webers CA, Schouten JS et al (2005) Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112:1177–1185
Pece A, Allegrini D, Montesano G et al (2016) Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study. Clin Ophthalmol 10:1131–1138
Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F et al (2012) Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 53:6214–6218